September 27, 2000JAMA
Current Role of Platelet Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Key result
Intravenous glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes in both conservative and invasive treatment strategies, whereas oral agents are not favorable.
Why the study?
Do Glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes?
Population
Patients with acute coronary syndromes (ACSs) from 10 randomized trials (each with 500 or more patients)
Comparison
Glycoprotein IIb/IIIa inhibitors vs Placebo
Design
Systematic_review
Authors
Discussion
Loading...
Member takes
Implication
IV GP IIb/IIIa inhibitors merit prominent ACS role across strategies; confirms RCT benefits while oral agents remain unfavorable.
Study Design
Type
Systematic Review
Structured PICO
Do Glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes?
P
Population
Patients with acute coronary syndromes (ACSs) from 10 randomized trials (each with 500 or more patients)
I
Intervention
Glycoprotein IIb/IIIa inhibitors (intravenous abciximab, eptifibatide, tirofiban hydrochloride, and oral agents)
C
Comparator
Placebo
O
Outcome
Clinical outcomes and bleeding risks
Intravenous glycoprotein IIb/IIIa inhibitors merit a prominent role in the initial management of acute coronary syndromes, while oral agents do not.
Limitations
- No head-to-head comparisons have been made of their clinical efficacy
Cite This Study
Deepak L. Bhatt (2000) conducted a systematic review in Acute Coronary Syndromes. Glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) vs. Placebo was evaluated. Intravenous glycoprotein IIb/IIIa inhibitors improve outcomes in patients with acute coronary syndromes in both conservative and invasive treatment strategies, whereas oral agents are not favorable.